Rationale: Anecdotal reports suggest that psychedelic drugs can improve psychological wellbeing and social engagement in autistic people. However, there are few contemporary studies on this topic.
Objectives: To examine autistic participants' experiences with psychedelic drugs and the extent to which they attributed changes in mental health and social engagement to their most 'impactful' psychedelic experience. We also explored associations between these changes and mechanistically important variables (e.g., aspects of the acute psychedelic experience and changes in 'psychological flexibility').
Methods: Self-selecting autistic participants (n = 233) with high autism quotient scores completed an online survey relating to their most impactful psychedelic experience. Questionnaires assessed the acute psychedelic experience and perceived psychedelic-induced changes in distress, social engagement and psychological flexibility, among other relevant variables.
Results: The majority of participants attributed reductions in psychological distress (82%) and social anxiety (78%) and increases in social engagement (70%) to their most 'impactful' psychedelic experience. A substantial minority (20%) also reported undesirable effects such as increases in anxiety with some describing their psychedelic experience as among the most negatively impactful experiences of their lives. The only substantial predictor of reductions in psychological distress was increased psychological flexibility.
Conclusion: Autistic people attributed changes in mental health and social engagement to a single highly impactful psychedelic experience. The results and their implications are discussed with caution considering the use of a non-experimental design and biased sampling.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00213-024-06685-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Endoscopic management of carefully selected asymptomatic body stuffers.
BMJ Case Rep
January 2025
Emergency Medicine, NorthShore University Health System, Manhasset, New York, USA.
The guidelines from the European and American Societies for Gastrointestinal Endoscopy discourage endoscopic retrieval of drug bags in body stuffers. However, recent evidence challenges this stance, demonstrating successful bag retrieval without fatal outcomes. We present two distinct cases illustrating varying outcomes of intervention.
View Article and Find Full Text PDFNeurotheology: Practical Applications with Regard to Integrative Psychiatry.
Curr Psychiatry Rep
January 2025
Department of Integrative Medicine and Nutritional Sciences, Thomas Jefferson University, 925 Chestnut Street, Suite 120, Philadelphia, PA, 19107, USA.
Purpose Of Review: Neurotheology is a nascent field of research and scholarship that seeks to understand the relationship between the brain and religious and spiritual phenomena. In the context of integrative psychiatry, neurotheology offers an intriguing intermediary between understanding how spirituality and religion affect brain function, and how this might be related to changes in mental health.
Recent Findings: A number of research studies over the years have observed that religious and spiritual beliefs, practices, and experiences can have a profound impact on a person's psyche.
Unveiling Psychedelics: One of the Most Meaningful Events in Life Associated with Improved Well-Being in Swedish Users.
J Psychoactive Drugs
January 2025
Child and Adolescent Psychiatry, Department of Clinical Sciences, Lund University, Lund, Sweden.
In the midst of growing research and societal discourse on psychedelic substances, a consistent finding is reported: A majority of users report profound personal meaning from their experiences. This pioneering study in Sweden, a nation renowned for its strict drug policies, sought to quantify the extent of reported meaningfulness among Swedish psychedelic users. Results revealed that a majority of the sample, 58%, ranked their psychedelic experience among the top 5 most meaningful events in their lives, while 85% among the top 10.
View Article and Find Full Text PDFPrimum Non Nocere: The Onus to Characterize the Potential Harms of Psychedelic Treatment.
Am J Psychiatry
January 2025
Department of Psychiatry, Center for the Neuroscience of Psychedelics, Massachusetts General Hospital, Boston (Ghaznavi, King, Rosenbaum); Department of Cardiology, Massachusetts General Hospital, Boston (Ruskin); Department of Psychiatry and Neurology, Chemical Neurobiology Laboratory, Center for the Neuroscience of Psychedelics, Massachusetts General Hospital, Boston (Haggerty); Havard Medical School, Boston (Ghaznavi, Ruskin, Haggerty, King, Rosenbaum).
The last few years have seen exponential growth in interest, investment, advocacy, and research into psychedelics as therapeutics. This reflects an optimism about the potential promise of psychedelics as therapeutics. As with all therapeutic interventions, research is needed not only into their benefits but also potential risks.
View Article and Find Full Text PDFSingle-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial.
Am J Psychiatry
January 2025
Institute for Advanced Diagnostics and Treatment, Sheppard Pratt Health System, Baltimore (Aaronson, Miller, LaPratt, Swartz, Shoultz, Lauterbach); Department of Psychiatry, University of Maryland, Baltimore (Aaronson, van der Vaart, Lauterbach); VA Palo Alto Health Care System and Department of Psychiatry and Behavioral Sciences Stanford University School of Medicine, Palo Alto, CA (Suppes); Departments of Psychiatry and Radiology, Columbia University, New York (Sackeim).
Article Synopsis
- The study focused on evaluating the safety and effectiveness of psilocybin for patients with severe treatment-resistant depression (TRD), who had not benefited from at least five previous treatments.
- Conducted over 12 weeks at Sheppard Pratt Hospital, patients received a single 25 mg dose of synthetic psilocybin and underwent therapy sessions before and after dosing, assessing their depression levels mainly with the Montgomery-Åsberg Depression Rating Scale (MADRS).
- Results showed significant reductions in depressive symptoms at both 3 weeks and 12 weeks post-treatment, indicating psilocybin’s potential as a viable option for individuals with severe TRD, although those with comorbid PTSD experienced less improvement.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!